To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
EY’s Arda Ural: Big pharma is driving a rebound in biopharma and medtech M&A
The most sought-after targets are small- to mid-sized companies focused on high-growth therapeutic areas, such as oncology, cardiometabolic, immunology, central nervous system and rare diseases.
